The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
News|Articles|May 4, 2026
5 Nephrology Headlines You Missed in April 2026
Author(s)Alex Hillenbrand
Fact checked by: Victoria Johnson
Catch up on 5 nephrology headlines you missed in April 2026, including WCN coverage, FDA updates, and trial data.
Advertisement
Advertisement
April 2026 marked a pivotal month in
Related to this article
The FDA has granted Priority Review to dersimelagon for EPP and XLP, setting a PDUFA date for late February 2027 as LEO Pharma completes its acquisition from Tanabe Pharma.
Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
Atacicept also stabilized eGFR and matched placebo on safety, with a full FDA approval filing planned for Q4 2026.
FDA accepts Cogent's bezuclastinib NDA for advanced systemic mastocytosis, backed by APEX trial data showing durable, high-rate responses.
Ameluz is now the first FDA-approved photodynamic therapy for a skin cancer, expanding use to superficial basal cell carcinoma (sBCC) in adults.
Phase 3 data show zasocitinib use led to clear or almost clear skin in around 70% of patients by Week 16, setting up an FDA decision in early 2027.
Advertisement
Advertisement